[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593278":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":17,"responsibleParty":34,"collaborators":7,"id":36,"slug":7,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Helene Masse, M.D","CONTACT","+33 2 53 48 28 57","helene.masse@chu-nantes.fr",{"name":15,"role":11,"phone":12,"phoneExt":7,"email":16},"Alexandra Poinas, PhD","alexandra.poinas@chu-nantes.fr",[18],{"facility":19,"status":20,"city":21,"state":21,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"CHU Nantes - Ophthalmology Department","RECRUITING","Nantes","44000","France",{"type":25,"coordinates":26},"Point",[27,28],-1.55336,47.21725,{"lat":28,"lon":27},[31],{"name":32,"role":11,"phone":33,"phoneExt":7,"email":16},"Alexandra Poinas","+33 2 40 08 33 33",{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100593278",false,"NCT07004361","Ethical Issues of Using Gene Therapy in the Treatment of AMD","Ethical Issues of Using Gene Therapy in the Treatment of AMD (Age-related Macular Degeneration)","Inclusion Criteria:\n\n* Patients with exsudative AMD, male female \\>18 years Patients for whom the doctor could consider gene therapy.\n\nExclusion Criteria:\n\nPatients with atrophic AMD (Age-related Macular Degeneration) Patients with other degenerative retinal diseases than AMD, Patients with with associated cognitive disorders.","ALL","18 Years",{"count":45,"type":46},30,"ESTIMATED","OBSERVATIONAL","The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence\u002Fnon-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.",[50],"Exudative Age-related Macular Degeneration",[52,53],"ethical","Age-related Macular Degeneration","2026-06-23",{"date":56,"type":57},"2026-06-24","ACTUAL",{"date":59,"type":57},"2025-07-01",{"date":61,"type":46},"2026-12",{"name":5,"class":6},1]